Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

The Safety, Tolerability and Biodistribution of a Single Intravenous Administration of Two Zirconium-89 Labelled Vartumabs (F8scFV or C9scFv) in Patients With Solid Tumors - a Phase 0, Open Label, PET/CT Molecular Imaging Basket Trial

Next Previous
Trial Profile

The Safety, Tolerability and Biodistribution of a Single Intravenous Administration of Two Zirconium-89 Labelled Vartumabs (F8scFV or C9scFv) in Patients With Solid Tumors - a Phase 0, Open Label, PET/CT Molecular Imaging Basket Trial

Status: Recruiting
Phase of Trial: Phase 0

Latest Information Update: 30 May 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Zirconium 89 Labelled Vartumab (Primary)
  • Indications Bladder cancer; Carcinoma; Chondrosarcoma; Colon cancer; Gastric cancer; Glioblastoma; Head and neck cancer; Hypopharyngeal cancer; Laryngeal cancer; Mouth neoplasm; Nasopharyngeal cancer; Non-small cell lung cancer; Oesophageal cancer; Oropharyngeal cancer; Osteosarcoma; Pancreatic cancer; Rectal cancer; Squamous cell cancer
  • Focus Adverse reactions; First in man; Pharmacokinetics
  • Acronyms VARTUTRACE
  • Sponsors VAR2 Pharmaceuticals

Most Recent Events

  • 24 Mar 2025 Primary endpoint time frame changed for Tumor-specific uptake of the IMP from [Time Frame: Day 1, 2, and 4 after dosing] to [Time Frame: Day 1 - 7 after dosing].
  • 30 Dec 2024 Planned End Date changed from 1 Oct 2025 to 1 Jan 2026.
  • 30 Dec 2024 Planned primary completion date changed from 1 Oct 2025 to 1 Jan 2026.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top